카지노 슬롯머신 규칙

카지노 슬롯머신 규칙 Bio announced plans for expanded technology out-licensing of its blood-brain barrier (BBB) shuttle platform, Grabody-B, during an online corporate presentation held on April 9. The company highlighted the platform’s compatibility with a wide range of modalities and target sites, positioning it for future partnerships.

On April 7, 카지노 슬롯머신 규칙 Bio signed a .9 billion technology transfer agreement with GlaxoSmithKline (GSK), granting GSK rights to apply Grabody-B to its own therapeutic candidates. Under the deal, 카지노 슬롯머신 규칙 Bio will provide preclinical and clinical data along with proprietary know-how. The agreement is viewed as a strong validation of Grabody-B’s commercial potential.

CEO Sanghoon Lee emphasized that the GSK partnership marks the beginning of broader licensing efforts. He noted that Grabody-B allows for exclusivity at the product level—rather than the target level—en카지노 슬롯머신 규칙ing multiple deals for distinct epitopes within the same disease area.

An epitope is a specific site on an antigen recognized by an antibody or T-cell receptor. Because drugs targeting different epitopes are considered separate therapies, 카지노 슬롯머신 규칙’s flexibility supports diverse development pipelines. For example, both Eli Lilly and Eisai are developing amyloid-beta antibodies targeting different epitopes, of which more than 10 are currently known. Similarly, tau proteins exhibit epitope variation based on modifications like phosphorylation and acetylation—further expanding potential applications.

Grabody-B’s scalability also spans multiple therapeutic modalities. 카지노 슬롯머신 규칙 Bio is working with Ionis Pharmaceuticals to adapt the platform for oligonucleotide-based drugs. The company plans to publish related research and believes Grabody-B could help resolve common issues such as liver toxicity and poor BBB penetration. “Grabody-B has demonstrated potential to overcome these limitations,” Lee stated.

Upcoming milestones include clinical data releases for 카지노 슬롯머신 규칙-104 and 카지노 슬롯머신 규칙-105—bispecific antibodies targeting breast cancer—and interim Phase 1 results for 카지노 슬롯머신 규칙-111. 카지노 슬롯머신 규칙-301, licensed to Sanofi for Parkinson’s disease, is in the final stage of its Phase 1 trial. 카지노 슬롯머신 규칙 Bio also aims to submit 카지노 슬롯머신 규칙001 for approval in 2026 as a second-line treatment for bile duct cancer.

Commenting on the GSK deal, Lee said, “While most existing BBB shuttles rely on the transferrin receptor (TfR), this agreement highlights the distinct advantages of our IGF1R-based 카지노 슬롯머신 규칙 platform.” He added that more licensing agreements are expected by pairing the platform with a variety of targets and modalities.